LEADER 01015nam0-22003611i-450- 001 990010046910403321 005 20160229123602.0 010 $a978-88-530-1030-8 035 $a001004691 035 $aFED01001004691 035 $a(Aleph)001004691FED01 035 $a001004691 100 $a20160229d2010----km-y0itay50------ba 101 1 $afre$bita 102 $aIT 105 $aa-------001yy 200 1 $aGrammathèque$egrammatica contrastiva per italiani$fLidia Parodi, Marina Vallacco 205 $a3. ed 210 $aGenova$cCIDEB$d2010 215 $a320 p.$cill.$d26 cm 610 0 $aLingua francese 676 $a448.2451$v22$zita 700 1$aParodi,$bLidia$0242303 701 1$aVallacco,$bMarina$0242304 801 0$aIT$bUNINA$gREICAT$2UNIMARC 901 $aBK 912 $a990010046910403321 952 $aXV Fb 203$b808/2016$fFSPBC 952 $aXV Fb 205$b810/2016$fFSPBC 952 $aXV Fb 204$b809/2016$fFSPBC 959 $aFSPBC 996 $aGrammathèque$9620341 997 $aUNINA LEADER 04023nam 22006615 450 001 9910298336303321 005 20200702125853.0 010 $a3-7091-1818-2 024 7 $a10.1007/978-3-7091-1818-4 035 $a(CKB)3710000000281304 035 $a(EBL)1966148 035 $a(OCoLC)899003845 035 $a(SSID)ssj0001385856 035 $a(PQKBManifestationID)11883459 035 $a(PQKBTitleCode)TC0001385856 035 $a(PQKBWorkID)11340615 035 $a(PQKB)10064177 035 $a(MiAaPQ)EBC1966148 035 $a(DE-He213)978-3-7091-1818-4 035 $a(PPN)18308778X 035 $a(EXLCZ)993710000000281304 100 $a20141113d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aNovel Technologies for Vaccine Development /$fedited by Igor S Lukashevich, Haval Shirwan 205 $a1st ed. 2014. 210 1$aVienna :$cSpringer Vienna :$cImprint: Springer,$d2014. 215 $a1 online resource (393 p.) 300 $aDescription based upon print version of record. 311 $a3-7091-1817-4 320 $aIncludes bibliographical references at the end of each chapters. 327 $aReverse Genetics Approaches for Rational Design of Inactivated and Live-Attenuated Influenza Vaccines -- Viral-Vectored Vaccines to Control Pathogenic Filoviruses -- Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention -- Current Status and Future of Polio Vaccines and Vaccination -- Current Status of Hantavirus Vaccines Development -- Experimental DNA-Launched Live Attenuated Vaccines against Infections Caused by Flavi- and Alphaviruses -- Sugar-Based Immune Adjuvants for Use in Recombinant, Viral, Vector, DNA and Other Styles of Vaccines -- Adenovirus-based Vectors for the Development of Prophylactic and Therapeutic Vaccines -- Radiovirotherapy for the Treatment of Cancer -- TRICOM Poxviral-Based Vaccines for the Treatment of Cancer -- The Use of Oncolytic Herpesvirus for the Treatment of Cancer -- SA-4-1BBL; A Novel form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines. 330 $aThis book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a ?must read? for all those involved in vaccine development, both in academia and industrial vaccine development. 606 $aVaccines 606 $aPharmaceutical technology 606 $aImmunology 606 $aVaccine$3https://scigraph.springernature.com/ontologies/product-market-codes/B16010 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000 615 0$aVaccines. 615 0$aPharmaceutical technology. 615 0$aImmunology. 615 14$aVaccine. 615 24$aPharmaceutical Sciences/Technology. 615 24$aImmunology. 676 $a610 676 $a615.19 676 $a615372 676 $a616079 702 $aLukashevich$b Igor S$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aShirwan$b Haval$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910298336303321 996 $aNovel Technologies for Vaccine Development$92498397 997 $aUNINA